More News! 2 Dec 2017 Kunstformen der Natur: 19th Century Biology Art in Exhibition Kunstformen der Natur, by Ernst Haeckel, is a beautiful series of prints that have influenced scientists and artists alike. A Dutch exhibition shows them like never before. In the fashion of the 19th century, Ernst Haeckel was simultaneously a biologist, philosopher, physician, and artist. A Darwin contemporary, although Haeckel supported Lamarckist and other evolutionary theories that are […] December 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2017 RNA Therapy for Rare Skin Disease Gets Orphan Status The EMA has granted orphan drug designation to ProQR’s QR-313, a possible first disease-modifying treatment for the rare disease dystrophic epidermolysis bullosa. Dystrophic epidermolysis bullosa (DEB) is a genetic disease that causes the skin to easily blister, severely affecting the quality of life of patients since a very early age. Current treatment is limited to […] November 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2017 Belgian Firm Raises €80M for Rapid Infection and Cancer Tests Biocartis is aiming to raise funds through a private placement of shares in order to support sales and further development of its rapid cancer tests. Based in Mechelen, Belgium, Biocartis focuses on developing fast, easy-to-use diagnostics. In order to boost its molecular diagnostics technology, the company launched a private equity placement of shares on Euronext […] November 29, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Nov 2017 Merck and Pfizer’s Checkpoint Inhibitor Fails to Treat Gastric Cancer Avelumab, marketed as Bavencio by Pfizer and Merck, has failed to show better efficacy than chemotherapy in a Phase III trial with gastric cancer patients. Merck (the German one) and Pfizer joined the checkpoint inhibitor club earlier this year with the approval of Bavencio (avelumab) in both the US and Europe. Looking to keep expanding the […] November 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 A Treatment for Sudden Deafness Fails in Phase III Auris Medical’s treatment for sudden deafness has failed to meet its efficacy endpoint, leading the company to terminate a second trial early. Based in Zug, Switzerland, Auris Medical is developing what could be the first treatments for inner ear disorders such as hearing loss, tinnitus, and vertigo. But today, the company suffered a setback. Its lead […] November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2017 New Gene Therapy for Parkinson’s will be Developed in the UK Synpromics and UCL will collaborate to develop a gene therapy to treat Parkinson’s disease that only targets specific neurons involved in the disease. Synpromics, based in Edinburgh, Scotland, is a company focusing on gene control. The biotech has decided to put its technology to use for the development of a gene therapy for Parkinson’s in […] November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2017 You Can Now Play DNA Tetris Thanks to This Irish Startup How cool would it be to program DNA at home to make gifs or play Tetris? Well, this device will soon let you do just that. Cell-Free Technologies wants to take synthetic biology out of the lab and into our homes. This startup based in Cork, Ireland, takes the molecular machinery that cells use to read […] November 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 27 Nov 2017 A First Treatment for Hearing Loss, Tinnitus and Vertigo? Meet the Man Behind It Thomas Meyer, CEO of Auris Medical, discusses how biotech can finally bring solutions to those who live with hearing loss, tinnitus and vertigo. Thomas Meyer is at the forefront of a wave of drugs that could, for the first time, show efficacy in treating common hearing disorders. In 2003, he founded Auris Medical to address […] November 27, 2017 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 23 Nov 2017 The Future is (Syn)Bio: How and when do we get there? Last week, Philip and I attended a meeting with some of the pioneers and leaders of the synthetic biology field. They believe biology will be everywhere in the future, but how do we get ready for it? Digital technologies are now present in almost all aspects of our lives. It seems obvious today that companies […] November 23, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Infographics 22 Nov 2017 Infographic: What is RNAi Therapy? Targeting the Untargetable Everything you need to know about what RNAi is, how it works and how it could soon change the way we treat all sorts of diseases. A new wave of therapies based on RNA interference is on the brink of making it to the market. A technology that was awarded the Nobel prize in 2006, […] November 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2017 Can this French Biotech Make it Easier to Rescue People from Hypoglycemia? Adocia’s ready-to-use glucagon has proved to be safe in phase I trials. The company believes it can overthrow Novo Nordisk and Eli Lilly in rescuing severe hypoglycemia. Based in Lyon, France, Adocia develops new formulations to improve the performance of diabetes drugs, including an ultra-rapid insulin to help type 1 diabetics control their blood glucose levels […] November 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2017 After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45% last month after releasing Phase III data for ViaSkin Peanut, a treatment delivered via a skin patch aimed at reducing peanut allergy in children aged […] November 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email